Abstract

Simple SummaryHigh-grade serous ovarian carcinoma (HGSOC) is the most aggressive histologic type of epithelial ovarian cancer, associated with high recurrence and mortality rates despite standard treatment. In accordance with the era of precision cancer medicine, we aimed to develop machine learning models predicting platinum sensitivity in patients with HGSOC. First, we collected patients’ clinicopathologic data from three tertiary hospitals. Second, we elected six variables associated with platinum sensitivity using the stepwise selection method. Third, based on these variables, predictive models were constructed using four machine learning algorithms, logistic regression (LR), random forest, support vector machine, and deep neural network. Evaluation of model performance with the five-fold cross-validation method identified the LR-based model as the best at identifying platinum-resistant cases. Lastly, we developed a web-based nomogram by fitting the LR model results for clinical utility. Based on the prediction results, physicians may implement individualized treatment and surveillance plans for each HGSOC patient.To support the implementation of individualized disease management, we aimed to develop machine learning models predicting platinum sensitivity in patients with high-grade serous ovarian carcinoma (HGSOC). We reviewed the medical records of 1002 eligible patients. Patients’ clinicopathologic characteristics, surgical findings, details of chemotherapy, treatment response, and survival outcomes were collected. Using the stepwise selection method, based on the area under the receiver operating characteristic curve (AUC) values, six variables associated with platinum sensitivity were selected: age, initial serum CA-125 levels, neoadjuvant chemotherapy, pelvic lymph node status, involvement of pelvic tissue other than the uterus and tubes, and involvement of the small bowel and mesentery. Based on these variables, predictive models were constructed using four machine learning algorithms, logistic regression (LR), random forest, support vector machine, and deep neural network; the model performance was evaluated with the five-fold cross-validation method. The LR-based model performed best at identifying platinum-resistant cases with an AUC of 0.741. Adding the FIGO stage and residual tumor size after debulking surgery did not improve model performance. Based on the six-variable LR model, we also developed a web-based nomogram. The presented models may be useful in clinical practice and research.

Highlights

  • Ovarian cancer accounted for approximately 313,959 new cases and 207,252 deaths in 2020, ranking eighth in both incidence and mortality among female cancers, globally [1]

  • From the Ovarian Cancer Cohort Database of each institution, we identified patients who met the following inclusion criteria: (1) aged ≥ 19 years; (2) pathologically confirmed high-grade serous ovarian carcinoma (HGSOC); (3) diagnosed between January 2000 and June 2019; and (4) underwent primary treatment, either primary debulking surgery (PDS) followed by platinum-based postoperative adjuvant chemotherapy or platinum-based neoadjuvant chemotherapy (NAC) followed by interval debulking surgery and postoperative adjuvant chemotherapy

  • Regardless of the validation set, the platinum-resistant group showed significantly worse PFS and overall survival (OS) than the platinum-sensitive group. These results suggest that the developed predictive model discriminates patients with good and poor survival outcomes well

Read more

Summary

Introduction

Ovarian cancer accounted for approximately 313,959 new cases and 207,252 deaths in 2020, ranking eighth in both incidence and mortality among female cancers, globally [1]. In the absence of cancer-specific symptoms and effective screening tools, epithelial ovarian cancer tends to be diagnosed at an advanced stage, leading to high recurrence and mortality rates despite treatment [5]. 90% of ovarian cancers are epithelial; high-grade serous ovarian carcinoma (HGSOC) is the most common and aggressive histologic ovarian cancer type [6]. Most HGSOC patients undergoing primary treatment are at high risk of recurrence due to chemoresistance [10]. Patients are divided into two groups according to the duration of a platinum-free interval (PFI), which is the time interval from the completion of platinum-based chemotherapy to disease progression [11]. Patients with PFI of

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call